Bristol-Myers Squibb Is Prepared To Heal Itself

This week I’m seeking a prestigious and long-term dividend-paying stock from the healthcare business sector. 

That healthcare sector includes ten industries all related to testing, diagnosing and treating what ails us. Healthcare industries are: biotechnology; diagnostics & research; drug manufacturers – major and – specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices; medical distribution; medical supplies.

Today I’m reviewing a large-cap drug manufacturer – major, named Bristol-Myers Squibb Company. Its trading ticker symbol is BMY. 

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has collaboration agreements with Nektar Therapeutics; Illumina, Inc.; Janssen Pharmaceuticals, Inc.; Advantagene, Inc.; and Compugen Ltd.; and Tsinghua University, as well as a research partnership with Sirenas. 

The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

I use three key data points to gauge the value of any dividend equity or fund like  Bristol-Myers Squibb Company (BMY): 

(1) Price

(2) Dividends

(3) Returns

Besides those three, four more keys will finally unlock an equity or fund in which to invest.

But those first three primary keys, best tell whether a company has made, is making, and will make money. 

BMY Price